Signature Estate & Investment Advisors LLC Takes $313,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Signature Estate & Investment Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 298 shares of the biopharmaceutical company’s stock, valued at approximately $313,000.

Other large investors have also recently bought and sold shares of the company. SteelPeak Wealth LLC grew its holdings in shares of Regeneron Pharmaceuticals by 173.0% in the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 692 shares during the period. Atria Investments Inc grew its holdings in Regeneron Pharmaceuticals by 12.2% in the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after purchasing an additional 941 shares during the last quarter. Tri Locum Partners LP increased its position in shares of Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after buying an additional 8,949 shares in the last quarter. Tidal Investments LLC raised its stake in shares of Regeneron Pharmaceuticals by 16.8% during the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after buying an additional 711 shares during the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $1,334,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on REGN. Barclays cut their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Royal Bank of Canada lowered their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Leerink Partners reissued a “market perform” rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $756.81 on Friday. The stock’s 50 day simple moving average is $985.21 and its 200 day simple moving average is $1,033.97. Regeneron Pharmaceuticals, Inc. has a 12-month low of $753.69 and a 12-month high of $1,211.20. The firm has a market cap of $83.17 billion, a P/E ratio of 18.73, a P/E/G ratio of 2.86 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.48% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.